FCM
Farallon Capital Management Portfolio holdings
AUM
$21.3B
This Quarter Return
-2.68%
1 Year Return
+23.12%
3 Year Return
+87.19%
5 Year Return
+183.94%
10 Year Return
+836.54%
AUM
$12.2B
AUM Growth
+$12.2B
(-15%)
Cap. Flow
-$622M
Cap. Flow
% of AUM
-5.09%
Top 10 Holdings %
Top 10 Hldgs %
49.99%
Holding
122
New
16
Increased
44
Reduced
27
Closed
23
Top Buys
| 1 |
AGN
Allergan plc
AGN
|
$881M |
| 2 |
IAC Inc
IAC
|
$318M |
| 3 |
Alibaba
BABA
|
$280M |
| 4 |
Alphabet (Google) Class C
GOOG
|
$131M |
| 5 |
BPL
Buckeye Partners, L.P.
BPL
|
$131M |
Top Sells
| 1 |
RHT
Red Hat Inc
RHT
|
$964M |
| 2 |
APC
Anadarko Petroleum
APC
|
$738M |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
$394M |
| 4 |
Booking.com
BKNG
|
$130M |
| 5 |
Equifax
EFX
|
$117M |
Sector Composition
| 1 | Healthcare | 42.86% |
| 2 | Technology | 14.15% |
| 3 | Communication Services | 11.41% |
| 4 | Industrials | 6.61% |
| 5 | Consumer Discretionary | 6.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
S
51
DELISTED
Sprint Corporation
S
| $38.5M | 0.29% |
6,234,186
-4,440,814
| -42% | -$27.4M |
|
|
PGNX
52
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $37.2M | 0.28% |
7,350,000
+1,806,614
| +33% | +$9.13M |
|
53
FibroGen
FGEN
$48.4M
| $37M | 0.28% |
1,000,000
-700,000
| -41% | -$25.9M |
|
54
NXP Semiconductors
NXPI
$57.5B
| $35.5M | 0.27% |
325,000
-105,000
| -24% | -$11.5M |
|
|
RC
55
Ready Capital
RC
$695M
| $35.1M | 0.27% |
2,205,132
-38,107
| -2% | -$607K |
|
56
Fate Therapeutics
FATE
$115M
| $34.9M | 0.26% |
2,250,000
-250,000
| -10% | -$3.88M |
|
57
Exelixis
EXEL
$9.95B
| $30.9M | 0.23% |
1,750,000
-1,250,000
| -42% | -$22.1M |
|
|
AMRN
58
Amarin Corp
AMRN
$311M
| $30.3M | 0.23% |
2,000,600
-2,249,400
| -53% | -$34.1M |
|
|
ZEAL
59
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
| $25.6M | 0.19% |
1,010,000
+10,000
| +1% | +$254K |
|
|
DCPH
60
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $25.5M | 0.19% |
+750,000
| New | +$25.5M |
|
|
NVTA
61
DELISTED
Invitae Corporation
NVTA
| $25.1M | 0.19% |
1,300,000
+400,000
| +44% | +$7.71M |
|
62
PTC Therapeutics
PTCT
$4.41B
| $24.6M | 0.19% |
726,986
+126,986
| +21% | +$4.29M |
|
63
Gen Digital
GEN
$18.3B
| $24.3M | 0.18% |
+1,030,000
| New | +$24.3M |
|
64
Veracyte
VCYT
$2.41B
| $24M | 0.18% |
1,000,000
+650,000
| +186% | +$15.6M |
|
|
STML
65
DELISTED
Stemline Therapeutics, Inc.
STML
| $23.9M | 0.18% |
2,300,000
+800,000
| +53% | +$8.33M |
|
|
MRTX
66
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $23.4M | 0.18% |
300,000
-695,000
| -70% | -$54.1M |
|
67
CRISPR Therapeutics
CRSP
$4.82B
| $23M | 0.17% |
560,367
+60,367
| +12% | +$2.47M |
|
|
TECX
68
Tectonic Therapeutic, Inc. Common Stock
TECX
$305M
| $21.9M | 0.17% |
1,550,000
+513,853
| +50% | +$7.26M |
|
|
ONCE
69
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $21.3M | 0.16% |
220,000
-550,000
| -71% | -$53.3M |
|
|
PVTL
70
DELISTED
Pivotal Software, Inc.
PVTL
| $21.3M | 0.16% |
+1,430,000
| New | +$21.3M |
|
71
Arrowhead Research
ARWR
$3.84B
| $18.3M | 0.14% |
650,000
-1,350,000
| -68% | -$38M |
|
72
Protagonist Therapeutics
PTGX
$3.62B
| $18M | 0.14% |
1,500,000
| – | – |
|
|
TCDA
73
DELISTED
Tricida, Inc. Common Stock
TCDA
| $15.4M | 0.12% |
+500,000
| New | +$15.4M |
|
|
RETA
74
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $14.6M | 0.11% |
182,060
-617,940
| -77% | -$49.6M |
|
|
MLNX
75
DELISTED
Mellanox Technologies, Ltd.
MLNX
| $13.7M | 0.1% |
+125,000
| New | +$13.7M |
|